Overactive Bladder - Results from #380

Relationship between the cross-sectional area of the lumbar dural sac and lower urinary tract symptoms: A population-based cross-sectional study. August 14, 2022

The effect of oral medications on fMRI brain activation: A randomized, double blind, controlled pilot trial of older women with overactive bladder. August 7, 2022

A Systematic Review and In Silico Study of Potential Genetic Markers Implicated in Cases of Overactive Bladder. August 7, 2022

Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA. July 31, 2022

Associations among Physician-Patient Communication, Patient Satisfaction, and Clinical Effectiveness of Overactive Bladder Medication: A Survey of Patients with Overactive Bladder. July 31, 2022

Neural networks outperform expert humans in predicting patient impressions of symptomatic improvement following overactive bladder treatment. July 31, 2022

Mirabegron in Overactive Bladder and Its Role in Exit Strategy After Botulinum Toxin Treatment in Children. July 24, 2022

Peroneal Electrical Transcutaneous NeuroModulation as a New Treatment for Patients with Overactive Bladder: An Initial Clinical Experience. July 24, 2022

Delivering patient-centered care through shared decision making in overactive bladder. July 24, 2022

Performance of urinary biomarkers in differentiating dysfunctional voiding in women with overactive bladder syndrome: a prospective pilot study. July 24, 2022

Intravesical Instillation of OnabotulinumtoxinA in the Treatment of Refractory Overactive Bladder in Participants with Urinary Incontinence. July 17, 2022

Feasibility of a Transcutaneous Tibial Nerve Stimulation Device Use in Overactive Bladder Patients: A Pilot Study From a Single Tertiary Care Center. July 17, 2022

Impact of Mirabegron Administration on the Blood Pressure and Pulse Rate in Patients with Overactive Bladder. July 17, 2022

Chapter 4: Treatment of overactive bladder in men: Is it really different? July 10, 2022

Efficacy and Safety of DA-8010, a Novel M3 Antagonist, in Patients With Overactive Bladder: A Randomized, Double-Blind Phase 2 Study. July 10, 2022

Evaluation of pelvic floor muscle elasticity in patients with overactive bladder syndrome using real-time tissue elastography. July 10, 2022

Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of Overactive Bladder in the European Economic Area, UK, and Switzerland July 5, 2022

Non-inferior and more feasible transcutaneous tibial nerve stimulation in treating overactive bladder: A systematic review and meta-analysis. July 3, 2022

Correlation between overactive bladder and detrusor overactivity: a retrospective study. July 3, 2022

How effectively do we apply first-line treatment in overactive bladder? July 3, 2022

Page 20 of 122